Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPETE: LAMA/LABA Combinations vs Tiotropium in COPD
NCT07541378Suspended
- Sponsor
- Medical University of Białystok
- Start
- Mar 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tiotropium, olodaterol, umeclidinium, vilanterol, indacaterol and 1 more in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Medical University of Białystok. Primary endpoint: Endurance time during constant-work-rate cycle ergometry (CWRCE) at 28 days. Started Mar 2024; status: suspended.
02
Drugs
tiotropiumolodaterolumeclidiniumvilanterolindacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07541378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07541378.